Filing Details

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. __N/A__)* Relmada Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 75955J402 (CUSIP Number) June 1, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [_] Rule 13d-1(b) [X] Rule 13d-1(c) [_] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 1. NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) RTW Investments, LP 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) [_] (b) [X] 3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 1,255,857 * 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 1,255,857 * 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,255,857 * 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)[_]11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 8.26%* 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) PN, OO, IA1. NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) RTW Master Fund, Ltd. 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) [_] (b) [X] 3. SEC USE ONLY4. CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 884,400 * 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 884,400 * 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 884,400 * 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.82%* 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO 1. NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Roderick Wong 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) [_] (b) [X] 3. SEC USE ONLYItem 1. (a). Name of Issuer: Relmada Therapeutics, Inc. (b). Address of issuer's principal executive offices: 880 Third Avenue, 12th FloorNew York, NY 10022 Item 2. (a). Name of person filing: RTW Investments, LP RTW Master Fund, Ltd. Roderick Wong (b). Address or principal business office or, if none, residence: RTW Investments, LP 412 West 15th Street Floor 9 New York, New York 10011RTW Master Fund, Ltd. c/o Intertrust Corporate Services (Cayman) Limited 190 Elgin Avenue, George Town Grand Cayman KY1-9001, Cayman Islands Roderick Wong c/o RTW Investments, LP 412 West 15th Street Floor 9 New York, New York 10011 (c). Citizenship: RTW Investments, LP ? Delaware RTW Master Fund, Ltd. ? Cayman Islands Roderick Wong ? United States of America (d). Title of class of securities: Common Stock (e). CUSIP No.: 75955J402Item 3. If This Statement is filed pursuant to ??.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a N/A Item 4. Ownership. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: RTW Investments, LP ? 1,255,857 * RTW Master Fund, Ltd. ? 884,400 * Roderick Wong ? 1,255,857 * (b) Percent of class: RTW Investments, LP ? 8.26%* RTW Master Fund, Ltd. ? 5.82%* Roderick Wong ? 8.26%* (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote RTW Investments, LP ? 0 RTW Master Fund, Ltd. ? 0 Roderick Wong ? 0 (ii) Shared power to vote or to direct the vote RTW Investments, LP ? 1,255,857 * RTW Master Fund, Ltd. ? 884,400 * Roderick Wong ? 1,255,857 * (iii) Sole power to dispose or to direct the disposition of RTW Investments, LP ? 0 RTW Master Fund, Ltd. ? 0 Roderick Wong ? 0 (iv) Shared power to dispose or to direct the disposition of RTW Investments, LP ? 1,255,857 * RTW Master Fund, Ltd. ? 884,400 * Roderick Wong ? 1,255,857 * * The Common Stock (the "Shares"), of Relmada Therapeutics, Inc. (the "Company") reported herein are held by RTW Master Fund, Ltd. and one or more private funds (together the "Funds") managed by RTW Investments, LP (the "Adviser"). The Adviser, in its capacity as the investment manager of the Funds, has the power to voteand the power to direct the disposition of all Shares held by the Funds. Accordingly, for the purposes of Reg. Section 240.13d-3, the Adviser may be deemed to beneficially own an aggregate of 1,255,857 Shares, or 8.26% of the Company?s 15,198,109 Shares deemed issued and outstanding as of May 13, 2020. Roderick Wong is the Managing Partner of the Adviser. This report shall not be deemed an admission that the Adviser, the Funds or any other person is the beneficial owner of the securities reported herein for purposes of Section 13 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the reporting persons herein disclaims beneficial ownership of the Shares reported herein except to the extent of the reporting person?s pecuniary interest therein.SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: June 10, 2020 RTW Investments, LP By: /s/ Roderick Wong Roderick Wong, Managing Partner RTW Master Fund, Ltd. By: /s/ Roderick Wong Roderick Wong, Director Roderick Wong By: /s/ Roderick Wong Roderick Wong, Individually The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature. Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent. Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001). Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Common Stock of Relmada Therapeutics, Inc. beneficially owned by them, together with any or all amendments thereto, when and if appropriate. The parties hereto further consent and agree to file this Joint Filing Statement pursuant to Rule13d-1(k)(1)(iii) as an exhibit to Schedule 13G, thereby incorporating the same into such Schedule13G. This Joint Filing Statement may be terminated by any of the undersigned upon written notice or such lesser period of notice as the undersigned may mutually agree. Dated: June 10, 2020 RTW Investments, LP By: /s/ Roderick Wong Roderick Wong, Managing Partner RTW Master Fund, Ltd. By: /s/ Roderick Wong Roderick Wong, Director Roderick Wong By: /s/ Roderick Wong Roderick Wong, Individually